TibaRay Awarded $400K Contract from the National Cancer Institute for Ultra-Rapid FLASH Beam Monitoring and Control Technology Development
The National Cancer Institute recently awarded TibaRay a $400K contract to develop a highly sensitive and ultra-fast radiation therapy (RT) FLASH dosimetry monitoring and control system. Conventional dose monitoring devices demonstrate non-linear behavior when used for FLASH RT applications, demanding the development of novel state-of-the-art hardware capable of measuring and controlling FLASH dose rates that are two to three orders of magnitude higher than conventional RT doses. Inclusive of this contract, TibaRay has now received funding of more than $10M from the Department of Energy and the National Institute of Health.
Read More...
The second annual FLASH Radiotherapy and Particle Therapy (FRPT) Conference was held in Barcelona, Spain in December 2022. More than 600 global participants attended the conference, whose objective was to promote the rigorous scientific study of FLASH therapy. Diverse presentation topics included studies exploring the fundamental biological mechanisms of FLASH therapy, technological developments, veterinary studies, and clinical trials. A common theme throughout the conference was the replication of the “FLASH effect" across multiple experimental models from independent researchers. Read More...
TibaRay proudly received the gold award – the highest honor possible – at the 5th Annual Global Innovation Start-Up Competition sponsored by Global Forum. Global Forum is an international, high-level, not-for-profit think-tank dedicated to the main technological, economic, social, societal, political, and ethical issues and challenges that affect the evolution of our digital society. Vinod Bharadwaj, Executive Vice President of TibaRay, represented the Company at the competition held in Muscat, Oman in October 2022.
Read More...